AffiliationDepartment of Respiratory Medicine, Mercy University Hospital, Cork, Ireland.
MeSHAntineoplastic Agents/chemistry/pharmacology/*therapeutic use
Epidermal Growth Factor/antagonists & inhibitors/metabolism
Lung Neoplasms/*drug therapy/metabolism
Signal Transduction/drug effects
Vascular Endothelial Growth Factor A/antagonists & inhibitors/metabolism
MetadataShow full item record
CitationCurr Med Chem. 2010;17(35):4291-325.
JournalCurrent medicinal chemistry
AbstractLung cancer is the leading cause of cancer death worldwide. Survival remains poor as approximately 80% of cases present with advanced stage disease. However, new treatments are emerging which offer hope to patients with advanced disease. Insights into cell biology have identified numerous intracellular and extracellular peptides that are pivotal in cancer cell signalling. Disrupting the function of these peptides inhibits intracellular signal transduction and diminishes uncontrolled proliferation, resistance to apoptosis and tumour angiogenesis. The most widely studied signalling pathway is the Epidermal Growth Factor (EGF) pathway. EGF signalling can be disrupted at numerous points. Blockade of the cell surface receptor is achieved by the monoclonal antibody cetuximab; intracellular tyrosine kinase activity is inhibited by erlotinib. Vascular Endothelial Growth Factor (VEGF) regulates another pathway important for tumour growth. Inhibition of VEGF impairs angiogenesis and disrupts metastatic spread. Bevacizumab is a monoclonal antibody that binds to VEGF and blocks interaction with its cell surface receptor. Clinical trials have demonstrated that disruption of these signalling pathways can improve survival in advanced lung cancer. New compounds including folate antimetabolites such as pemetrexed, proteasome inhibitors such as bortezomib, modified glutathione analogues such as TLK286, and other agents such as epothilones and other small molecules are currently being evaluated in patients with lung cancer. As more and more signalling peptides are targeted for manipulation, it is hoped that a new era is dawning in the treatment of advanced stage lung cancer. This review will focus on emerging new therapies in the management of lung cancer.
- Targeted therapy in advanced non-small-cell lung cancer.
- Authors: Gettinger S
- Issue date: 2008 Jun
- Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
- Authors: Kelly K, Huang C
- Issue date: 2008 Jun
- The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
- Authors: Langer C, Soria JC
- Issue date: 2010 Mar 1
- Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
- Authors: Pakkala S, Ramalingam SS
- Issue date: 2009 Mar
- Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
- Authors: Cabebe E, Wakelee H
- Issue date: 2007 Feb